FIDAS-5 NEW
| Price | $54 | $77 | $118 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-07-22 |
Product Details
| Product Name: FIDAS-5 | CAS No.: 1391934-98-7 |
| Purity: 97.66% | Supply Ability: 10g |
| Release date: 2025/07/22 |
Product Introduction
Bioactivity
| Name | FIDAS-5 |
| Description | FIDAS-5 is an orally active methionine adenosyltransferase 2A (MAT2A) inhibitor with an IC50 of 2.1 μM. It can effectively compete with S-adenosylmethionine for MAT2A binding and has anticancer effects. |
| In vitro | METHODS: FIDAS-5 (3 μM; 36 hours) was used to treat LS174T cells, and the levels of S-adenosylmethionine (SAM) and S-adenosylhomocysteine ??(SAH) were observed. RESULTS FIDAS-5 reduced S-adenosylmethionine (SAM) and S-adenosylhomocysteine ??(SAH) levels in LS174T cells. METHODS: FIDAS-5 (3 μM; 7 days) was used to treat LS174T cells, and the proliferation of LS174T cells was observed. RESULTS FIDAS-5 significantly inhibited the proliferation of LS174T cells. METHODS: FIDAS-5 (3 μM) treatment inhibited LS174T colorectal cancer cells, and the expression of c-Myc and cyclinD1 in LS174T colorectal cancer cells was observed by westernBlot. RESULTS FIDAS-5 inhibited the expression of c-Myc and cyclinD1 in LS174T colorectal cancer cells [1]. METHODS: OPM2 cells were transduced with siMAT2A or scrambled siRNA for 3 days. MAT2A-silenced and parental OPM2 cells were treated with different doses of FIDAS-5 (0.5, 1, 2 μM) to determine whether FIDAS-5 indeed impairs MM cell survival by inhibiting the enzymatic activity of MAT2A. RESULTS The antitumor effect of FIDAS-5 on MAT2A-silenced cells was impaired compared with cells transduced with scrambled siRNA. FIDAS-5 indeed inhibited MM cell survival in part by targeting MAT2A. [2] |
| In vivo | METHODS: Tumors were induced in athymic nude mice by subcutaneous injection of HT29 CRC cells. FIDAS-5 treatment (20 mg/kg) was administered orally via gavage. The oral efficacy of FIDAS-5 on HT29 tumor xenografts in nude mice was tested by measuring tumors twice weekly using digital calipers. RESULTS FIDAS-5 significantly inhibited xenograft tumor growth with minimal body weight differences. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 125 mg/mL (477.61 mM), Sonication is recommended. |
| Keywords | SAM | SAH | S-adenosylmethionine | p21WAF1/CIP1 | Methionine S-adenosyltransferase 2A(MAT2A) | MAT2A | Inhibitor | inhibit | FIDAS-5 | FIDAS5 | FIDAS 5 | CyclinD1 | colorectal | c-Myc | anti-proliferation | anti-cancer |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $44.00/5mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2025-07-25 | |
| $0.00/1g |
VIP5Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2021-09-28 | |
| $0.00/25KG |
VIP6Y
|
Hebei Mujin Biotechnology Co.,Ltd
|
2023-06-28 | |
| $54.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2025-07-16 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY